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INTRODUCTION
The migration of cells is an important aspect of many biologic
events, such as wound healing, tumor cell metastasis and
embryonic development (Lauffenberger and Horwitz, 1996).
During the formation of atherosclerotic plaques and in
restenosis following angioplasty the migration and
proliferation of smooth muscle cells are key events (Ross,
1993). Vascular smooth muscle cells have insulin-like growth
factor I (IGF-I) receptors and respond to exogenously added
IGF-I with increased protein and DNA synthesis (Conover,
1991; Clemmons, 1984) and increased migration (Bornfeldt et
al., 1993).
In previous studies we have demonstrated that ligand
occupancy of the αVβ3 integrin receptor is required for IGF-
I induced migration of vascular smooth muscle cells (SMC)
(Jones et al., 1996). In the absence of serum, these cells will
migrate in response to IGF-I only if they are plated on
vitronectin, an αVβ3 ligand. Blocking ligand occupancy of
αVβ3 with either the disintegrin echistatin or the αVβ3
specific monoclonal antibody (LM609) results in marked
attenuation of the IGF-I induced increase in migration (Jones
et al., 1996). One explanation for these data is that blocking
ligand occupancy of an integrin receptor inhibits IGF-I
stimulated migration by blocking physical contact with the
extracellular matrix and thereby blocking the physical forces
required for migration. However, our subsequent studies
demonstrated that blocking ligand occupancy of the αVβ3
receptor with echistatin, in cells that were attached to
their ECM, also blocked IGF-I stimulated DNA and
protein synthesis and inhibited IGF-I induced receptor
autophosphorylation. This suggests that ligand occupancy of
the αVβ3 receptor was required for full activation of the IGF-
I receptor and intracellular signaling by IGF-I (Zheng and
Clemmons, 1998). 
The β3 subunit of the αVβ3 receptor has been implicated as
the major link between the integrins and the cytoskeleton and
as an anchor for important components of several transduction
systems (Sastry and Horwitz, 1993). Some of these binding
interactions and signaling functions have been shown to require
specific residues within the cytoplasmic domain of β3, in
particular the two tyrosines (Tyr747) (Tyr759).
The common experimental paradigm used to investigate
integrin signaling involves detaching adherent cells from tissue
culture plates and replating them on surfaces coated with
purified ECM proteins. Signaling events are then examined
over a short period of time as cells reattach. In many of these
studies the cells that are being analyzed have been derived from
1417
The disintegrin echistatin inhibits ligand occupancy of the
αVβ3 integrin and reduces Insulin-like growth factor I
(IGF-I) stimulated migration, DNA synthesis, and receptor
autophosphorylation in smooth muscle cells. This suggests
that ligand occupancy of the αVβ3 receptor is required for
full activation of the IGF-I receptor.
Transfection of the full-length β3 subunit into CHO cells
that have no endogenous β3 and do not migrate in response
to IGF-I was sufficient for IGF-I to stimulate migration of
these anchorage dependent cells. In contrast, transfection
of either of two truncated mutant forms of β3 (terminating
at W715 or E731) or a mutant with substitutions for Tyr 747
Tyr 759(YY) into either CHO or into porcine smooth muscle
cells did not restore the capacity of these cells to migrate
across a surface in response to IGF-I. This effect was not
due to loss of IGF-I receptor autophosphorylation since the
response of the receptor to IGF-I was similar in cells
expressing either the full-length or any of the mutant forms
of the β3 subunit. Echistatin reduced IGF-I receptor
phosphorylation in cells expressing the full-length or the
YY mutant forms of β3 subunit, but it had no effect in cells
expressing either of two truncated forms of β3. A cell-
permeable peptide homologous to the C-terminal region
of the β3 subunit (amino acids 747-762) reduced IGF-I
stimulated migration and receptor autophosphorylation of
non-transfected porcine smooth muscle cells. These results
demonstrate that the full-length β3 with intact tyrosines at
positions 747 and 759 is required for CHO cells to migrate
in response to IGF-I. Furthermore, a region of critical
amino acids between residues 742-762 is required for
echistatin to induce its regulatory effect on receptor
phosphorylation. Since the IGF-I receptor does not bind to
αVβ3 the results suggest that specific but distinct regions
of the β3 subunit interact with intermediary proteins to
facilitate IGF-I stimulated cell migration and echistatin
induced inhibition of IGF-I signal transduction.
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solid tissues and therefore the use of this model is not an
accurate reflection of the tissue context in which integrins and
growth factors normally co-operate to regulate cellular
responses. It is therefore important to distinguish between the
role of integrin signaling in response to cellular reattachment
and the co-operative signaling between integrins and growth
factor receptors that occurs in cells that have been stably
attached for prolonged periods.
An important step in understanding the mechanistic basis of
the interaction between the αVβ3 integrin and the IGF-I
receptor is to define the signaling components that are activated
by ligand occupancy of αVβ3 and how this signal is
transmitted to the IGF-I receptor. In previous studies, we have
shown that there is no direct interaction between the IGF-I
receptor and αVβ3 (Zheng and Clemmons, 1998). Therefore
as a first step to better define the mechanism, we have
attempted to identify the regions of the β3 subunit that are
required for IGF-I mediated signaling. Using in vitro
mutagenesis, we modified the structure of the β3 subunit and
in particular the two tyrosines and determined if these changes
altered IGF-I stimulated cell migration or the effect of the
disintegrin antagonist echistatin on IGF receptor linked
signaling using cells that had stably attached to their ECM for
a prolonged time period. 
MATERIALS AND METHODS
All chemicals were purchased from the Sigma Chemical Company (St
Louis, MO) unless otherwise stated. Porcine aortic SMCs (pSMC)
were obtained as previously described (Gockerman et al., 1995).
CHO-K1 cells were obtained from the American Type Culture
Collection (Rockville, MD). An anti-β3 integrin receptor subunit
polyclonal antibody was purchased from Chemicon International
(Temecula, Ca). A polyclonal anti-IGF-I receptor antiserum and a
monoclonal phosphotyrosine antibody (PY99) were purchased from
Santa Cruz (Santa Cruz Ca). IGF-I was a gift from Genentech (South
San Franscisco, CA). EZ-link Sulfo NHS SS biotin, Supersignal
chemiluminescence substrate and the BCA protein assay kit were
purchased from Pierce (Rockford, Il).
Synthesis of cell-permeable synthetic peptides
Peptides were synthesized by step-wise solid phase peptide synthesis
method and purified by C18 reverse-phase high performance liquid
chromatography by the Peptide Synthesis Facility at the University of
North Carolina, Chapel Hill. The cell permeable peptides were
designed using the hydrophobic VTVLALGALALVGVG region of
the signal peptide sequence of human β3 followed by either the
last 16 amino acids of the human β3 cytoplasmic tail,
YKEATSTFTNITYRGT (test peptide) or the last 16 amino acids of
the human β1 cytoplasmic tail YKSAVTTVVNPKYEGK (control
peptide).
Generation of expression vectors
Full-length human integrin β3 receptor subunit cDNA (kindly
provided by Dr G. White UNC Chapel Hill) was subcloned into both
the pRcRSV and pMEP4 expression vectors (Invitrogen, Carlsbad,
CA). 
Generation of truncated forms of the β3 receptor
The two truncated forms (termed WK and E) of the β3 receptor were
generated using single stranded mutagenesis with mutagenic primers
that were complementary to the full-length β3 cDNA, but which also
introduced an XbaI restriction endonuclease site and a stop codon,
resulting in truncation at either amino acid residue 715 (WK) or 731
(E). For the WK mutant, the primer was complementary to nucleotides
2235-2255, except for a base change indicated by * to introduce the
XbaI site: 5′-GAT GAG GAG TTT CT*A GAT GAG-3′. For the E
mutant the primer was complementary to nucleotide 2277-2301,
except for base changes indicated by * to introduce the XbaI site: 5′-
GCG TTC TTT* CT*A GA*A TTT TCG CTT-3′. In both cases the
introduced XbaI site is underlined. The pRcRSV plasmid was digested
at the introduced XbaI site using 100 units/ml, and at the XbaI site
that was present in the polylinker of the pRcRSV vector. The vector
and truncated insert were then relegated and the modified DNA was
then subcloned into pMEP4. 
Generation of Tyr 747Phe/Tyr 759Phe mutant β3
The polymerase chain reaction was used to mutate the full-length β3
coding sequence at tyrosines 747 and 759 by using a mutagenic primer
(5′-TTA AGT GCC CCG GAA CGT GAT ATT GGT GAA GGT
AGA CGT GGC CTC TTT AAA CAG TGG GTT GTT GG-3′). The
full-length β3 cDNA was used as a template. The N-terminal primer
sequence used was 5′-ATG CGA GCG CGC CCG CGG CC-3′.
Following sequencing to confirm mutagenesis, the polymerase chain
reaction product was subcloned into pRcRSV and pMEP4. 
The sequences of the native human β3 cytoplasmic tail and the
truncated and mutant receptors that were generated and expressed are
shown in Fig. 1.
Transfection of CHO-K1 cells and pSMCs
CHO-K1 cells were transfected with the pRcRSV expression vector
containing either the full-length β3 DNA or one of the truncated or
mutant forms of the receptor or vector alone (control). G418 resistant
CHO-K1 clones were selected in αMEM containing 5% FBS with
800 µg/ml G418 and positive clones were maintained in alpha MEM
containing 5% FBS with 400 µg/ml G418 (growth medium). The
pSMCs (passage 4) were transfected with the pMEP4 expression
vector. In all cases transfections were performed using the poly-l
ornithine method as previously described (Imai et al., 1997).
Hygromycin resistant pSMCs were selected and maintained in
DMEM-H containing 15% FBS and 100 µg/ml hygromycin (growth
medium). Both transfected and non-transfected pSMCs were used in
subsequent experiments between passage 6 and 20. 
Biotinylation of cell surface proteins to detect β3
expression
Transfected cells were grown to subconfluency, rinsed three times











Fig. 1.Diagram showing the sites of the
two truncations introduced into the β3
integrin receptor cytoplasmic tail and the
position of the two tyrosine residues
substituted with phenylalanine. The
expression vectors were constructed and
CHO-K1 cells and pSMCs were
transfected as described in Materials and
Methods.
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with ice-cold PBS (pH 8.0) then incubated at 4°C for 30 minutes with
PBS + 0.5 mg/ml biotin. Cells were then washed three times with PBS
+ glycine (15 mM) to quench the biotinylation. Cells were then lysed
as described below and the protein content of each sample was
measured. An equal amount of protein from each cell lysate was
immunoprecipitated with a 1:300 dilution of a polyclonal anti human
β3 antibody as described below. The immune complexes were then
separated by SDS-PAGE, 8% gel, under non-reducing conditions.
Biotinylated β3 was visualized by immunoblotting with peroxidase
conjugated ExtrAvidin as described below.
Immunoprecipitation for the detection of biotinylated
proteins, IGF-I receptor or focal adhesion kinase (FAK)
phosphorylation
Cells were cell-surface biotinylated as described above, or incubated
overnight in serum-free DMEM (SFM) plus 0.01% BSA and then
exposed to 100 ng/ml IGF-I for various lengths of time prior to lysis
in RIPA buffer (1% NP40, 0.25% sodium deoxycholate, 1 mM
EGTA, 150 mM sodium chloride, 50 mM Tris-HCl, pH 7.5, 1 mM
sodium orthovanadate, 1 mM sodium fluoride, 1 mM PMSF, 1 µg/ml
pepstatin A, 1 µg/ml leupeptin, 1 µg/ml aprotinin). The lysates were
clarified by centrifugation at 14,000 g for 10 minutes. The
supernatant was incubated overnight at 4°C with either a 1:300
dilution of an IGF-I receptor antibody or a 1:300 dilution of a
monoclonal antiphosphotyrosine antibody (PY99). Immune
complexes were then precipitated by adding Protein A-Sepharose
and incubating for a further 2 hours at 4°C. The samples were then
centrifuged at 14,000 g for 10 minutes and the pellets washed 4
times with RIPA buffer. The pellet was suspended in 45 µl of
Laemmli buffer and boiled for 5 minutes and the proteins separated
by SDS-PAGE, 8% gel. To examine the effect of echistatin on IGF-
I receptor phosphorylation cells were incubated overnight in SFM
plus 0.01% BSA and 10−8 M echistatin prior to exposure of cells to
IGF-I. To examine the effect of the synthetic peptides, cells were
incubated in SFM plus 0.01% BSA overnight then incubated with
either the test or control peptide (50 µM) for 6 hours prior to
exposing the cells to IGF-I (100 ng/ml).
Western immunoblotting
Following SDS-PAGE proteins were transferred to PVDF membrane.
The membranes were blocked in 1% BSA in Tris-buffered saline with
0.1% Tween (TBST) for 2 hours at room temperature. The membranes
were incubated with primary antibody (monoclonal anti-
phosphotyrosine (PY99) at 1:10,000 dilution, or polyclonal anti-FAK
at 1:500 dilution) overnight at 4°C or peroxidase-conjugated
ExtrAvidin (1:1,000) for one hour at room temperature. Following
incubation with primary antibodies membranes were then washed
three times in TBST prior to incubation with appropriate horseradish
peroxidase-conjugated secondary antibody. Binding of the peroxidase
label was visualized using enhanced chemiluminescence using the
manufacturer’s instructions (Pierce, Rockford IL).
Cell wounding and migration assay
On plastic
Cells were plated in six-well plates (Falcon Labware, Division of
Beckton Dickinson Fairborne NJ) in growth medium. pSMCs were
grown to confluency over six days with one medium change and
CHOs were grown to confluency in three days. Wounding was
performed as previously described (Jones et al., 1993). Briefly, a razor
blade was used to scrape an area of cells leaving a denuded area and
a sharp visible wound line. The wounded monolayers were then rinsed
three times in SFM and then ten 1 mm areas along the wound edge
were selected and recorded for each treatment. The wounded
monolayers were then incubated with SFM (plus 2% FBS pSMCs
only) with or without 100 ng/ml IGF-I for 24-48 hours at 37°C. The
cells were then fixed and stained (Diff Quick, Dade Behring, Inc.,
Newark, DE) and the number of cells migrating into the wound area
counted. At least five of the previously selected 1 mm areas at the
edge of the wound were counted for each data point. 
To test the effect of the synthetic peptides on IGF-I stimulated
migration, cells were incubated for 6 hours after wounding with either
50 µM of test or control peptide. The medium was aspirated, and the
peptide was then re-added with IGF-I (100 ng/ml) and the incubation
continued for 48 hours.
On vitronectin
Six well plates were coated with human vitronectin (purified as
previously described) at a concentration of 5 µg/ml in PBS plus 1 mM
CaCl2 overnight at 4°C. Subconfluent cells were dislodged and
resuspended in SFM + 0.01% BSA and plated onto the coated wells
to achieve 80-90% confluency following attachment and spreading
overnight at 37°C. Wounding was then performed as described above,
but cells were incubated with SFM containing 0.01% BSA and the
individual treatments.
Our previous analysis of the wounded monolayer by [3H]thymidine
autoradiography demonstrated that the labeling index of pSMCs at the
wounded edge was 7±4% at the basal level and 18±7% after treatment
with IGF-I. Therefore, less than 10% of cells present in the denuded
area at the end of the migration assay are considered to result from
cell division rather than cell migration (Jones et al., 1996).
The Mann-Whitney test and Student’s t-test were used to compare
differences between the control and test groups. Band intensities on
autoradiographs were measured by scanning densitometry and
analyzed using NIH Image, version 1.61.
RESULTS
Expression of human β3 integrin receptor
To determine if the human β3 that was expressed following
transfection was localized on the cell surface, cell impermeable
biotin was utilized and the biotinylated cell surface proteins
were immunoprecipitated with anti-human β3 antiserum. Fig.
2 shows the cell surface expression of human β3 integrin
receptor in CHO-K1 cells (A) and pSMC cells (B). CHO-K1
Fig. 2.Constitutive expression of full-length, truncated or mutant
forms of the human β3 integrin receptor in CHO-K1 cells (A) or
pSMCs (B). CHO-K1 cells and pSMC cells were transfected with the
different human β3 integrin receptor constructs and positive clones
were selected as described in Materials and Methods. Following cell
surface biotinylation, equal amounts of cell lysate were
immunoprecipitated with a β3 polyclonal antibody. Biotinylated
proteins were then visualized with peroxidase conjugated
ExtrAvidin. This figure is representative of the level of β3 expression
in the clones used for this study. Lane 1, full-length β3 receptor; lane
2, WK mutant receptor; lane 3, E mutant receptor; lane 4, empty
vector (con); lane 5, Tyr747Phe/Tyr759/Phe (YY) mutant receptor.
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cells transfected with empty vector alone (control) have no
detectable β3 integrin receptor by immunoblotting; however,
following transfection with expression vectors encoding either
the full-length, truncated, or double tyrosine mutant forms of
the receptor, a single band at approximately 90 kDa is
detectable, corresponding to the expected size of β3 run under
non-reducing conditions. In the pSMC transfected with the
empty vector alone there is a band at 90 kDa corresponding to
endogenous porcine β3; however, following transfection with
expression vectors encoding the full-length and the mutant
forms of human β3 there is an increase in the level of
detectable human β3. Successful transfected expression of
human β3 was confirmed by reverse transcriptase-polymerase
chain reaction (data not shown). 
Integrin β3 expression permits IGF-I stimulated
migration in CHO-K1 cells
To establish a role for the β3 subunit of the αVβ3 integrin
receptor in IGF-I-stimulated migration, the IGF-I stimulated
response of CHO-K1 cells transfected with the full-length
human β3 receptor was compared with cells transfected with
the empty vector. Fig. 3 shows that CHO-K1 cells transfected
with the empty vector alone do not increase their migration in
response to IGF-I. However, following transfection with the
full-length human β3 receptor, IGF-I stimulated a 79±28%
(mean ± s.e.m. n=3) increase in migration in cells plated and
grown on plastic and a 95±8.5% (mean ± s.e.m. n=3) increase
if they had been plated on vitronectin. As the β3 subunit is
required for high affinity vitronectin binding, the results further
confirm that IGF-I stimulated migration of adherent cells is
mediated through the αVβ3 receptor.
Since the β3 subunit of the αVβ3 receptor is required for
IGF-I stimulated migration we used this model system to
further define the region of the subunit required for this
response. CHO-K1 cells expressing either of the two
truncated forms of the receptor (WK,E) or the receptor
with the double tyrosine substitution (YY) showed no
increase in migration following incubation with IGF-I (Fig.
3). A lack of response to IGF-I was observed whether the
cells were grown on plastic (A) or plated on vitronectin (B).
In comparison control pSMCs that express a full-length wild-
type porcine β3 subunit migrated normally in response to
IGF-I (194±38% increase, mean ± s.e.m. n=3). In cells
transfected with the full-length human β3 subunit there was
a similar response (IGF-I stimulated migration by 194±28%
mean ± s.e.m. n=3). In contrast, pSMCs expressing either
of the truncated forms of the human β3 subunit or the
double tyrosine mutant receptor demonstrated no significant
increase in migration in the presence of IGF-I (124±24,
136±18, and 107±8%, p, NS, respectively) (mean ± s.e.m.
n=3) (Table 1).
A cell-permeable synthetic peptide homologous to
the C-terminal region of β3 reduces IGF-I stimulated
migration
In order to further substantiate our data using a non-transfected
physiologically relevant cell model we used a technique that
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Table 1. Cell migration of pSMCs expressing the different
forms of the β3 integrin receptor compared with control
cells transfected with the empty vector alone
Cell migration 
Cell type (% control)* P‡
Control 194±38 P<0.05




Cells were plated at 80-90% confluency on 6-well plates pre-coated with
vitronectin. Following wounding cell migration was determined in the
presence or absence of IGF-I (100 ng/ml). For each treatment at least 5
different pre-selected 1 mm wound areas were counted. 
*Results shown are calculated from the mean ± s.e.m. from 3 independent
experiments. The number of cells migrating in the absence of IGF-I is
expressed as 100%. Results shown are expressed as the percentage of cells
migrating in the presence of IGF-I compared with the same cell type
migrating in the absence of IGF-I.
‡P<0.05 when treatment without IGF-I is compared with treatment with
IGF-I.
Fig. 3.Cell migration of CHO-K1
cells transfected with the full-length
β3 integrin receptor, truncated or
mutant forms of the receptor compared
with migration of empty vector
transfected cells. Cells were grown to
confluency on uncoated 6-well plates
(A) or plated at 80-90% confluency on
6-well plates pre-coated with
vitronectin (B). In both cases cells
were then wounded and cell migration
was determined in the presence or
absence of IGF-I (100 ng/ml). For
each treatment at least 5 different 1mm
pre-selected wound areas were
counted. Results shown are calculated
from the mean ± s.e.m. from 3
independent experiments. The number
of cells migrating in the absence of
IGF-I is expressed as 100%. The results shown are expressed as the percent of cells migrating in the presence of IGF-I compared with the same















































Control   Full      WK       E       YY
length
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results in the uptake of a small synthetic peptide sequence
homologous to the C-terminal region of the β3 receptor. The
addition of an extra 20 amino acids from the signal sequence
of β3 results in the uptake of this peptide into the cell
cytoplasm where it presumably can compete with the
endogenous receptor for signaling molecules. This technique
has already been used by other laboratories to begin to identify
the functional role of different regions of both β3 (Liu et al.,
1996) and β1 integrins (Buttery et al., 1999) for cell attachment
or platelet activation. 
A 6-hour pre-incubation of non-transfected pSMCs with the
synthetic peptide prior to incubation with IGF-I, while having
no effect on basal migration resulted in a significant decrease
in IGF-I-induced migration (36±5%, mean ± s.e.m. n=4,
P<0.05 when migration in the presence of test peptide and IGF-
I is compared with migration in the presence of IGF-I alone).
The control peptide had no effect on migration in the presence
or absence of IGF-I (Fig. 4). 
The β3 integrin receptor cytoplasmic tail is not
required for FAK phosphorylation but is required for
IGF-I stimulated FAK dephosphorylation
The tyrosine phosphorylation, and its associated activation,
of FAK have been implicated as a key event in integrin
mediated signal transduction. IGF-I has been reported to
stimulate both phosphorylation and dephosphorylation of
FAK depending upon the cell type and experimental design
(Casamassima and Rozengurt, 1998; Baron et al., 1998;
Guvakova and Surmacz, 1999). We therefore compared the
levels of phosphorylated FAK in confluent monolayer
cultures expressing the full-length β3 integrin subunit with
the level of phosphorylated FAK in cells expressing the
truncated form of β3 (WK). In addition we compared the
effect of IGF-I treatment on FAK phosphorylation in the same
two cell types.
It can be seen in Fig. 5A that there is no detectable
difference in basal levels of FAK phosphorylation between
pSMCs expressing the full-length or truncated form of β3.
Similar results were obtained when CHO cells expressing
the different forms of β3 were compared (Fig. 5B). When
pSMCs expressing the full-length β3 were treated with
IGF-I a marked decrease in FAK phosphorylation was
apparent at 10 minutes, this decrease was transient as levels
r turned to base line following 20 minutes treatment with
IGF-I. In contrast, exposure of stably anchored cells
expressing the truncated form of β3 (WK) to IGF-I resulted
in no apparent change in the level of FAK phosphorylation.
Similar results were obtained with the CHO cells expressing
the full-length β3 except the rate of FAK dephosphorylation
was slower i.e. no decrease was seen until 30 minutes IGF-I
treatment (Fig. 5B). Again no decrease in FAK
phosphorylation is apparent in CHO cells expressing the
truncated form of β3 (Fig. 5B).
The β3 integrin receptor subunit cytoplasmic tail is
not required for IGF-I receptor phosphorylation
Following a 10-minute incubation of pSMC with IGF-I
there was no difference in the level of IGF-I receptor
phosphorylation between cells expressing the full-length β3
receptor (Fig. 6A) or either of the two truncated of the receptor
forms or the receptor with the double tyrosine substitution. The
level of phosphorylation after IGF-I stimulation was
comparable to that seen in the control cells (Fig. 6A). This
finding was further supported by the results with CHO-K1 cells
shown in Fig. 6B. There was a marked increase in the level of
IGF-I receptor phosphorylation following stimulation with
































Fig. 4.Cell migration of non-transfected pSMCs incubated with a
cell-permeable synthetic peptide homologous to the C-terminal
region of the human β3 integrin receptor. Cells were grown to
confluency on 6-well plastic dishes then wounded and pre-incubated
with 50 µM of the test or control peptide with and without IGF-I
(100 ng/ml) as described in Materials and Methods. The number of
cells migrating across the wound at 8 pre-selected 1 mm regions of
the wound was counted. Results shown are the mean ± s.e.m. from
one representative experiment that was repeated four times with
similar results. **P<0.05 when migration in the presence of IGF-I is
compared with migration in the absence of IGF-I. ‡P<0.05 when
migration in the presence of IGF-I test peptide is compared with
migration in the presence of IGF-I alone.
Fig. 5.FAK phosphorylation in cells expressing full-length or
truncated (WK) forms of the human β3 integrin receptor with or
without exposure to IGF-I. Cells were grown to 80-90% confluency
in 10 cm2 plastic dishes in growth medium and then incubated
overnight in SFM plus 0.01% BSA. The cells were then exposed to
IGF-I for either 10, 20 or 30 minutes (pSMCs) or 30 minutes
(CHOs). Following cell lysis and immunoprecipitation with an
antiphosphotyrosine antibody, the amount of FAK in each sample
was determined by immunoblotting with an anti FAK antibody.
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alone, i.e. with no β3 expression. The level of phosphorylation
was comparable to that seen in cells expressing the full-length
receptor and in the cells expressing both of the truncated forms
of the receptor as well as in cells expressing the receptor with
the double tyrosine substitution. 
The cytoplasmic tail of the β3 integrin receptor
subunit is required for the inhibitory effect of
echistatin on IGF-I stimulated receptor
phosphorylation
Our previous results demonstrating that blocking ligand
occupancy of the αVβ3 integrin receptor with the
disintegrin echistatin attenuated IGF-I cellular responses
suggested a direct relationship between the activation state
of the integrin receptor and full activation of the IGF-I
signaling. Having demonstrated that the cytoplasmic tail of
β3 is not required for IGF-I receptor phosphorylation we
next tested whether echistatin could still have an inhibitory
effect on the receptor in the absence of the β3 cytoplasmic
tail.
Fig. 6A shows that pre-incubation of pSMCs transfected
with the empty vector alone or the full-length β3 receptor with
echistatin resulted in a significant reduction in the level of IGF-
I receptor phosphorylation, a 33±0.75% and 32±0.5% (± s.e.m.
n=3, P<0.05) reduction, respectively, when analyzed by
scanning densitometry. However, echistatin had no effect on
the level of IGF-I receptor phosphorylation in cells expressing
either of the two truncated forms of the receptor. In contrast,
echistatin still had a significant inhibitory effect on IGF-I
receptor phosphorylation in cells expressing the receptor with
the double tyrosine substitution, a 29.5±1.25% (± s.e.m. n=3,
P<0.05) reduction.
Fig. 6B shows similar results were obtained with the CHO-
K1 cells. Echistatin had no inhibitory effect on IGF-I receptor
phosphorylation in cells transfected with the empty vector
alone consistent with the absence of β3. As with the pSMCs,
echistatin had a negative effect on the level of IGF-I receptor
phosphorylation in cells expressing the full-length β3
receptor (a 42.7±1.25% (± s.e.m. n=3, P<0.005) reduction).
Again, echistatin had no effect in cells expressing either of
the two truncated forms of the receptor. As with the pSMCs,
the CHO cells expressing the receptor with the double
tyrosine substitution were sensitive to the effects of
echistatin, resulting in a 23.7±0.65% (± s.e.m. n=3, P<0.005)
reduction in phosphorylation when analyzed by scanning
densitometry.
A cell-permeable synthetic peptide homologous to
e C-terminal region of β3 reduces IGF-I receptor
phosphorylation
Although our findings with transfected CHO cells suggested
that an intact β3 subunit was not required for IGF-I to stimulate
receptor phosphorylation, they do not exclude the possibility
that in the presence of full-length β3 both ligand occupancy of
β3 and a full complement of β3 protein interactions, as well as
the IGF-I receptor occupancy, is required for optimal IGF-I
receptor phosphorylation. To investigate that possibility,
nontransfected pSMC were pre-incubated with the cell-
permeable peptide that had been shown to inhibit IGF-I
stimulated migration. This resulted in significant inhibition of
IGF-I stimulated receptor phosphorylation. When analyzed by
scanning densitometry, the test peptide reduced the level of
IGF-I receptor phosphorylation by 20±3.6% (± s.e.m. n=3,
P<0.05, when the level of IGF-I receptor phosphorylation in
the presence of test peptide is compared with IGF-I receptor
phosphorylation in the absence of peptide) whereas the control
peptide had no effect. A representative experiment is shown in
Fig. 7.
DISCUSSION
I  previous studies that utilized stably attached cells, we have
demonstrated a requirement for ligand occupancy of the αVβ3
integrin receptor for optimal IGF-I receptor-mediated signaling
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Fig. 6. IGF-I receptor phosphorylation in cells expressing the
different forms of the human β3 integrin receptor in the presence
or absence of echistatin. Cells were grown to 80-90% confluency
in 10cm2 plastic dishes in growth medium and then incubated
overnight in SFM plus 0.01% BSA with or without 10−8 M
echistatin. The cells were then exposed to IGF-I for either 10
minutes (pSMCs) or 3 minutes (CHOs). Following cell lysis and
immunoprecipitation of the IGF-I receptor, the phosphorylation
of the IGF-I receptor in each sample was determined by
immunoblotting with an anti-phosphotyrosine antibody.
(A) pSMCs expressing the different forms of the human β3
integrin receptor. (B) CHO-K1 cells expressing the different
forms of the human β3 integrin receptor. This figure is
representative of results obtained from 3 separate experiments. 
Fig. 7. IGF-I receptor phosphorylation of untransfected pSMCs
following pre-preincubation with the synthetic peptide homologous
to the C-terminal of the human β3 integrin receptor. Cells were
grown to 80-90% confluency in 10 cm2 plastic dishes in growth
medium and then incubated overnight in SFM plus 0.01% BSA.
Cells were then incubated for a further 6 hours with 50 µM of the
test or control peptide. Cells were then exposed to IGF-I (100 ng/ml)
for 10 minutes. Following cell lysis and immunoprecipitation of the
IGF-I receptor, phosphorylation of the IGF-I receptor in each sample
was determined by immunoblotting.
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(Jones et al., 1996; Zheng and Clemmons, 1998). In this study
we have analyzed this interaction by determining in stably
attached cells the role of cytoplasmic tail of the β3 subunit in
modulating both IGF-I-stimulated migration and IGF-I
receptor phosphorylation. Using two independent experimental
approaches we have shown that the C-terminal region of the
β3 cytoplasmic tail is required for both IGF-I stimulated
migration and the inhibitory effect of echistatin on IGF-I
receptor phosphorylation. A crucial role for the C-terminal
region of β3 and more specifically for Tyr747, Tyr759 in IGF-I
stimulated migration is supported by other studies of β3
integrin function. Phosphorylation of Tyr747 has been
demonstrated following platelet aggregation and the signaling
proteins SHC and Grb2, have been shown to associate with
phosphorylated β3 peptides (Law et al., 1996). Law et al. have
shown that mutation of these tyrosines results in defective
αIIbβ3 function in mice (Law et al., 1999). The 744NPXY
sequence of β3 was shown to be essential for melanoma cell
migration on vitronectin but in that study that key structural
requirement was the presence of a tyrosine residue and not its
phosphorylated state (Filardo et al., 1995). A blocking peptide
comparable to that used in this study was shown to block
adhesion of melanoma cells to vitronectin and mutation of
Tyr747 and Tyr759 resulted in loss of the inhibitory function of
this peptide (Liu et al., 1996). Although we have not identified
the specific protein(s) that interact with the C-terminal region
of β3 to modulate the cell migration response, our results
suggest that there is an interaction between such a protein and
either one of the downstream (post receptor) signaling
elements in a pathway that is activated by the IGF-I receptor
or some intracellular protein that is induced by IGF-I. 
The disentegrin echistatin, has been shown to be a potent
inhibitor of the IGF-I receptor phosphorylation response
(Zheng and Clemmons, 1998) and in these studies it was
unable to exert an inhibitory effect on receptor phosphorylation
in the absence of a β3 cytoplasmamic tail. This result would
predict that cells expressing truncated β3 would have an
attenuated IGF-I receptor phosphorylation response. In
contrast, the level of IGF-I receptor phosphorylation was
equivalent in cells expressing different forms of the receptor.
However, if β3 signaling to the IGF-I receptor had no effect on
IGF-I stimulated receptor phosphorylation, then it would be
predicted that the cell permeable β3 peptides would also have
no effect. Since they were effective we propose an alternative
explanation that is based on the fact that integrin function can
be altered by different intracellular signals. These signals
regulate integrin conformation, ligand affinity, and activation
of signal transduction. The αVβ3 integrin has been shown to
be present in a constitively high or low affinity state and the
low affinity state can be induced by intracellular suppressors
(Wary et al., 1998). We propose that under basal conditions
wherein there is no ligand occupancy, the β3 integrin functions
through intermediary proteins to suppress IGF-I receptor
phosphorylation (Fig. 8). When β3 is occupied by an
appropriate ligand such as vitronectin, this suppression is lifted
allowing IGF-I mediated receptor activation. In this model,
truncation or absence of the β3 receptor does not result in the
loss of the ability of IGF-I to reduce receptor phosphorylation
but rather also functions to lift suppression resulting in no
change in the ability of IGF-I to activate the receptor when
compared the full-length β3 that is ligand occupied. Exposure
of cells to echistatin prevents the lifting of this suppression by
igands therefore resulting in a reduction in IGF-I receptor
phosphorylation. Since in our cells expressing truncated β3
there was no suppression at baseline, it is predictable that
chistatin would have no effect. Also echistatin may have
additional functional activities. Echistatin binding to αVβ3 has
been shown to induce extensive conformational changes
(Cheresh and Spiro, 1987). It is possible that a conformational
change in β3 may be an additional mechanism by which the
interaction between β3 and β3-linked signaling molecules is
perturbed. The β3 synthetic peptides which have been shown
i  other studies to compete with signaling molecules for
binding to β3 (Liu et al., 1996) clearly disrupted the receptor
phosphorylation response to IGF-I suggesting that they
effected this change by altering the binding of intermediary
signaling molecules to β3 thus perturbing the mechanism by
which ligand occupancy of β3 acts to lift suppression. The
elucidation of the components of this signaling mechanism will
be an important goal in future studies. 
The tyrosine phosphorylation of FAK is considered a key
event in integrin mediated signal transduction. FAK
phosphorylation is an initial event that follows cellular
adhesion to ECM proteins in a number of different cell types
(Burridge et al., 1992; Guan and Shalloway, 1992; Kornberg
et al., 1992). Integrin-engagement triggered phosphorylation
of FAK creates binding sites for SH2 domains of other
signaling molecules, thus providing a link between integrin
engagement and downstream signaling events (Cobb et al.,
1994; Schaller et al., 1994; Calab et al., 1995). Cells from
Ligand Occupancy of the
αVβ3 integrin receptor
Lifting of an intracellular repressor
Associated with the β3 cytoplasmic domain
Positive co-operation




Truncation of the β3
 cytoplasmic domain
Constitutive co-operation between
Integrin and IGF-I receptor 
No association of 
intracellular repressor
Fig. 8. Ligand occupancy of the αVβ3
integrin lifts the intracellular repression
associated with the β3 integrin resulting in
postive co-operation between the integrin and
IGF-I receptor. In the presence of echistatin
the repression can not be lifted and there is no
positive co-operation between the two
receptors. Truncation of the β3 cytoplasmic
tail prevents association of the intracellular
repressor resulting in constitutive co-
operation between the two receptors.
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FAK−/− mice have reduced migration compared with their
wild-type counterparts (Ilic et al, 1995). In contrast to other
growth factors, IGF-I has been shown to both promote both
FAK phosphorylation and dephosphorylation depending upon
the cell type and experimental design (Casamissma and
Rozengurt, 1998; Baron et al., 1998; Guvakova and Surmacz,
1999) Our results using stably attached cells show that in
contrast to recently attached cells, stimulation of FAK
phosphorylation is not required for IGF-I to stimulate cell
migration. Additionally, although integrin beta subunit
cytoplasmic domains are important for the activation of
attachment-mediated FAK phosphorylation, in stably
attached cells the truncation of the β3 cytoplasmic tail had no
effect on the basal level of FAK phosphorylation. 
In contrast, IGF-I did induce a rapid and transient decrease
in FAK phosphorylation in cells expressing the full-length β3,
but it had no effect on the cells expressing the truncated form
of the β3. Attenuation of FAK dephosphorylation in response
to IGF-I was shown to be associated with reduced IGF-I
stimulated migration in MCF-7 breast cancer cells expressing
a catalytically inactive SHP-2 mutant (Manes et al., 1999).
Reduced spreading and migration of fibroblasts from SHP-2−/−
mice has also been reported (Yu et al., 1998). Since
hyperphosphorylation of FAK is also observed in these mice,
it was hypothesized that the SHP-2 phosphatase could mediate
FAK dephosphorylation and turnover required for motility and
spreading. The role of the β3 cytoplasmic tail in the FAK
dephosphorylation response to IGF-I is as yet unclear,
however, since SHP-2 is a cytosolic phosphatase and FAK
localizes to focal adhesions following integrin engagement,
one hypothesis is that truncation of the β3 cytoplasmic tail
prevents the IGF-I stimulated recruitment of SHP-2 from the
cytosol to the focal adhesions and the lack of FAK turnover
prevents localized cell detachment that may be required for
migration. 
In summary, our studies have begun to uncover the
complexity of the integrin/IGF-I receptor interaction by
demonstrating that, in stably anchored cells, different
components of the cytoplasmic tail of β3 are required for
different aspects of IGF-I signaling. The identification of the
exact regions of this integrin receptor that affect the different
aspects of IGF-I signaling offers the potential to specifically
modify selected IGF-I mediated effects without disrupting
others. 
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